Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression: Correlation with androgen independence

Rajal B. Shah, Debashis Ghosh, James T. Elder

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-naïve group. CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.

Original languageEnglish (US)
Pages (from-to)1437-1444
Number of pages8
JournalProstate
Volume66
Issue number13
DOIs
StatePublished - Sep 13 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Androgens
Prostatic Neoplasms
Hormones
Neoplasms
Seminal Vesicles
Proportional Hazards Models
Odds Ratio
Carcinoma
Pharmaceutical Preparations
Therapeutics

Keywords

  • Androgen independence
  • Epidermal growth factor receptor
  • Prostate cancer
  • Tumor progression

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression : Correlation with androgen independence. / Shah, Rajal B.; Ghosh, Debashis; Elder, James T.

In: Prostate, Vol. 66, No. 13, 13.09.2006, p. 1437-1444.

Research output: Contribution to journalArticle

@article{947609a4a22a46a18d0451502cd9d557,
title = "Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression: Correlation with androgen independence",
abstract = "BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95{\%} CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-na{\"i}ve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-na{\"i}ve group. CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.",
keywords = "Androgen independence, Epidermal growth factor receptor, Prostate cancer, Tumor progression",
author = "Shah, {Rajal B.} and Debashis Ghosh and Elder, {James T.}",
year = "2006",
month = "9",
day = "13",
doi = "10.1002/pros.20460",
language = "English (US)",
volume = "66",
pages = "1437--1444",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

TY - JOUR

T1 - Epidermal growth factor receptor (ErbBI) expression in prostate cancer progression

T2 - Correlation with androgen independence

AU - Shah, Rajal B.

AU - Ghosh, Debashis

AU - Elder, James T.

PY - 2006/9/13

Y1 - 2006/9/13

N2 - BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-naïve group. CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.

AB - BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-naïve group. CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.

KW - Androgen independence

KW - Epidermal growth factor receptor

KW - Prostate cancer

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=33748460152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748460152&partnerID=8YFLogxK

U2 - 10.1002/pros.20460

DO - 10.1002/pros.20460

M3 - Article

C2 - 16741920

AN - SCOPUS:33748460152

VL - 66

SP - 1437

EP - 1444

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 13

ER -